Rome, 14 Sept. (Adnkronos Health) – “The pharmaceutical industry has never stopped. Even at the dawn of the pandemic” of Covid-19, “the first thing we asked was to recognize the strategic role of the sector and we got it inserted in a law. We therefore had the opportunity to produce without interruption in an extremely complicated situation because the decrees relating to safety measures had not yet been defined. So every company has organized itself seriously and continued to produce while maintaining the safe distancing for their employees “. This was underlined by Enrica Giorgetti, general manager of Farmindustria, speaking this morning at the inauguration of ‘Labio 4.0 Marino Golinelli’ in the Alfasigma di Pomezia plant.
“We have never stopped – he recalled – In that period our companies also had problems of logistics and supply, and directly or through the association we have maintained constant and direct contact with the Regions and even with individual hospitals. The truly extraordinary thing, which highlights the passion of our entrepreneurs and our companies, is that in some cases the companies have reconverted the existing production chains to produce gels or other drugs that were missing at that time. there has never been a lack of medicines available to patients with other pathologies “.
Giorgetti then highlighted the role of the pharmaceutical industry “which does not give up to contribute to people’s health and to collaborate with institutions. The figure of the period of the pandemic is that, through constant collaboration, it has been possible to ensure health for the citizens. We must now continue to work in this direction to create a favorable climate for attracting investments, otherwise our competitors, including countries like France and Germany, will overtake us “, he warned.
In this regard, he added, “let’s not forget that a competition law is being developed that calls into question the value of the patent. Research is long and risky – said Giorgetti – and it is necessary that the pharmaceutical companies that invest in this sector are protected. Mine is a cry of alarm to avoid measures that could undermine the attractiveness of investments in the country and the territories, such as Lazio, which is the first export of medicines. Furthermore, I would like to emphasize that we are in serious delay in the definition of the decrees on clinical trials, a theme that I like to mention here “.
And on Labio 4.0 he commented: “Today is a day of celebration because a new creature was born, a creature devoted to innovation and therefore it is right to celebrate it. The emotion is great also because after 2 years of isolation we have recreated today, for the first time, the sense of community. The participation of many colleagues and many Italian pharmaceutical companies that are present at this event is proof of this “.